Cargando…
FADD as a key molecular player in cancer progression
Cancer is a leading disease-related cause of death worldwide. Despite advances in therapeutic interventions, cancer remains a major global public health problem. Cancer pathogenesis is extremely intricate and largely unknown. Fas-associated protein with death domain (FADD) was initially identified a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644706/ https://www.ncbi.nlm.nih.gov/pubmed/36348274 http://dx.doi.org/10.1186/s10020-022-00560-y |
_version_ | 1784826801096228864 |
---|---|
author | Liu, Ying Li, Xiaoge Zhou, Xuehao Wang, Jianxun Ao, Xiang |
author_facet | Liu, Ying Li, Xiaoge Zhou, Xuehao Wang, Jianxun Ao, Xiang |
author_sort | Liu, Ying |
collection | PubMed |
description | Cancer is a leading disease-related cause of death worldwide. Despite advances in therapeutic interventions, cancer remains a major global public health problem. Cancer pathogenesis is extremely intricate and largely unknown. Fas-associated protein with death domain (FADD) was initially identified as an adaptor protein for death receptor-mediated extrinsic apoptosis. Recent evidence suggests that FADD plays a vital role in non-apoptotic cellular processes, such as proliferation, autophagy, and necroptosis. FADD expression and activity of are modulated by a complicated network of processes, such as DNA methylation, non-coding RNA, and post-translational modification. FADD dysregulation has been shown to be closely associated with the pathogenesis of numerous types of cancer. However, the detailed mechanisms of FADD dysregulation involved in cancer progression are still not fully understood. This review mainly summarizes recent findings on the structure, functions, and regulatory mechanisms of FADD and focuses on its role in cancer progression. The clinical implications of FADD as a biomarker and therapeutic target for cancer patients are also discussed. The information reviewed herein may expand researchers’ understanding of FADD and contribute to the development of FADD-based therapeutic strategies for cancer patients. |
format | Online Article Text |
id | pubmed-9644706 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96447062022-11-15 FADD as a key molecular player in cancer progression Liu, Ying Li, Xiaoge Zhou, Xuehao Wang, Jianxun Ao, Xiang Mol Med Review Cancer is a leading disease-related cause of death worldwide. Despite advances in therapeutic interventions, cancer remains a major global public health problem. Cancer pathogenesis is extremely intricate and largely unknown. Fas-associated protein with death domain (FADD) was initially identified as an adaptor protein for death receptor-mediated extrinsic apoptosis. Recent evidence suggests that FADD plays a vital role in non-apoptotic cellular processes, such as proliferation, autophagy, and necroptosis. FADD expression and activity of are modulated by a complicated network of processes, such as DNA methylation, non-coding RNA, and post-translational modification. FADD dysregulation has been shown to be closely associated with the pathogenesis of numerous types of cancer. However, the detailed mechanisms of FADD dysregulation involved in cancer progression are still not fully understood. This review mainly summarizes recent findings on the structure, functions, and regulatory mechanisms of FADD and focuses on its role in cancer progression. The clinical implications of FADD as a biomarker and therapeutic target for cancer patients are also discussed. The information reviewed herein may expand researchers’ understanding of FADD and contribute to the development of FADD-based therapeutic strategies for cancer patients. BioMed Central 2022-11-08 /pmc/articles/PMC9644706/ /pubmed/36348274 http://dx.doi.org/10.1186/s10020-022-00560-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Liu, Ying Li, Xiaoge Zhou, Xuehao Wang, Jianxun Ao, Xiang FADD as a key molecular player in cancer progression |
title | FADD as a key molecular player in cancer progression |
title_full | FADD as a key molecular player in cancer progression |
title_fullStr | FADD as a key molecular player in cancer progression |
title_full_unstemmed | FADD as a key molecular player in cancer progression |
title_short | FADD as a key molecular player in cancer progression |
title_sort | fadd as a key molecular player in cancer progression |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644706/ https://www.ncbi.nlm.nih.gov/pubmed/36348274 http://dx.doi.org/10.1186/s10020-022-00560-y |
work_keys_str_mv | AT liuying faddasakeymolecularplayerincancerprogression AT lixiaoge faddasakeymolecularplayerincancerprogression AT zhouxuehao faddasakeymolecularplayerincancerprogression AT wangjianxun faddasakeymolecularplayerincancerprogression AT aoxiang faddasakeymolecularplayerincancerprogression |